Anavex's blarcamesine achieves pre-specified efficacy in phase iib/iii alzheimer's trial: data presented at ctad conference 2024

Data of blarcamesine confirm upstream sigmar1 activation presented as late breaking oral communications at clinical trials on alzheimer's disease (ctad) conference 2024 oral, once daily blarcamesine meaningfully slowed clinical decline for early alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events new york, oct. 31, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including alzheimer's disease, parkinson's disease, rett syndrome, schizophrenia, and other central nervous system (cns) diseases, today presented new data from the phase iib/iii study showing that blarcamesine (anavex®2-73), once daily orally, demonstrates pre-specified clinical efficacy through upstream sigmar1 activation. clinical data confirmed the mechanism of action (moa) by pre-specified sigmar1 gene analysis in people with early alzheimer's disease (ad).
AVXL Ratings Summary
AVXL Quant Ranking